Pfizer gets worldwide rights to GlycoMimetics lead compound GMI1070; deal terminated
Executive Summary
Glycobiology specialist GlycoMimetics Inc. (creating small molecules with similar structures and activities to those of bioactive carbohydrates) has licensed Pfizer Inc. exclusive global rights to its Phase II E-, P-, and L-selectin antagonist GMI1070 for vaso-occlusive crisis associated with sickle cell disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice